Get the Stockscreener App
137.37
1.25%
1.70
Pre-market:
137.98
0.61
+0.44%
Biogen Inc stock is traded at $137.37, with a volume of 1.68M.
It is up +1.25% in the last 24 hours and up +0.48% over the past month.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
See More
Previous Close:
$135.67
Open:
$136.79
24h Volume:
1.68M
Relative Volume:
1.15
Market Cap:
$20.14B
Revenue:
$9.61B
Net Income/Loss:
$1.53B
P/E Ratio:
13.13
EPS:
10.46
Net Cash Flow:
$1.85B
1W Performance:
-3.60%
1M Performance:
+0.48%
6M Performance:
-3.55%
1Y Performance:
-29.04%
1-Day Range:
$135.81
$138.00
1-Week Range:
$135.41
$142.64
52-Week Range:
$110.03
$197.70
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
137.37 | 19.89B | 9.61B | 1.53B | 1.85B | 10.46 |
|
LLY
Lilly Eli Co
|
724.54 | 640.60B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
179.71 | 428.03B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
220.61 | 386.06B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
123.65 | 236.62B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
78.56 | 193.83B | 63.43B | 16.42B | 14.72B | 6.49 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
Biogen, Eisai Say China Approves Maintenance Dosing Regimen for Alzheimer's Drug - MarketScreener
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China - Biogen
Biogen (BIIB) Secures Approval for LEQEMBI's Monthly Dosing in C - GuruFocus
Eisai and Biogen Announce Approval of LEQEMBI® for Maintenance Dosing in Alzheimer's Disease Treatment in China - Quiver Quantitative
Biogen Inc. (BIIB): A Bull Case Theory - Yahoo
What drives Biogen Inc stock priceMomentum Stock Picks & Bull Bear Market Updates - earlytimes.in
What analysts say about Biogen Inc IDP stockInstitutional Buying Trends & Minimal Investment Trading Plans - Early Times
A Look at Biogen’s (BIIB) Valuation Following FDA Feedback on Spinraza High-Dose Application - simplywall.st
Biogen (BIIB): Reevaluating Valuation Following FDA’s Supplemental Spinraza Dose Setback - Yahoo Finance
Biogen (BIIB) Expands Neurology Pipeline With Alcyone Buyout, Stock Seen Undervalued - Yahoo
Biogen CoLab sparks Harvard student's biotech career journeyBizwomen - The Business Journals
Fierce Biotech Layoff Tracker 2025: Heidelberg reduces headcount by 75%; Biogen trims team - Fierce Biotech
BIOGEN : TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS OCTOBER 30, 2025 - MarketScreener
Biogen to Report Third Quarter 2025 Financial Results October 30, 2025 - Biogen
Exclusive: Biogen calls it quits on AAV gene therapy, again - Endpoints News
What's Going On With Biogen StockBiogen (NASDAQ:BIIB) - Benzinga
Jefferies sees positive triggers for Biogen's stockinitiates with a buy rating. - MarketScreener
Jefferies bullish on Biogen Alzheimer’s drug, pipeline By Investing.com - Investing.com Canada
This Lululemon Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Jefferies Initiates Coverage of Biogen (BIIB) with Buy Recommendation - Nasdaq
National Ataxia Foundation Partners with Biogen to Bring Bill Nye "the Science Guy" Back To the Lab With New Series About Friedreich Ataxia - WV News
Jefferies Initiates Coverage on Biogen (BIIB) with Buy Rating | - GuruFocus
Jefferies initiates Biogen stock with Buy rating, $190 price target By Investing.com - Investing.com Nigeria
Jefferies initiates Biogen stock with Buy rating, $190 price target - Investing.com India
Biogen, Eisai win regulatory nod in Australia for Alzheimer’s treatment - medwatch.com
United States Inflammatory Bowel Disease Market Growth Fueled - openPR.com
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Biogen at Bernstein Insights: Strategic Pipeline Focus - Investing.com
Viatris Nixes Biogen's Extra 1-Year Protection Over MS Drug - Law360
Biogen’s high-dose Spinraza turned down by FDA due to CMC troubles - Yahoo Finance
BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL - Yahoo Finance
FDA denies approval for higher dose of nusinersen for SMA - SMA News Today
EU judges cut Biogen’s monopoly on multiple sclerosis drug Tecfidera - Courthouse News
Biogen (NASDAQ:BIIB) Receives "Hold" Rating from Needham & Company LLC - MarketBeat
Australian Approval Boosts Biogen (BIIB) Alzheimer's Treatment - GuruFocus
Biogen (BIIB) Faces Minor Setback with FDA Response on Spinraza Dosage - GuruFocus
Biogen gets ‘unexpected’ CRL for high-dose Spinraza, will submit more technical data - Endpoints News
LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia - GlobeNewswire
425,000 Patients Affected: Australia Approves LEQEMBI for Early Alzheimer's Disease Treatment - Stock Titan
Biogen gets CRL for high dose nusinersen - The Pharma Letter
Biogen Inc. $BIIB Shares Bought by Parallel Advisors LLC - MarketBeat
Mn Services Vermogensbeheer B.V. Buys New Shares in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Shares Sold by Swedbank AB - MarketBeat
Biogen complete response letter manageable, says Citi - TipRanks
Biogen (BIIB) Analyst Rating Reiterated as Hold by Needham | BII - GuruFocus
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia - JCN Newswire
FDA knocks back Biogen's high-dose Spinraza - pharmaphorum
Wall Street Zen Downgrades Biogen (NASDAQ:BIIB) to Buy - MarketBeat
FDA issues complete response letter for Biogen’s high-dose SMA drug - Investing.com Australia
FDA issues complete response letter for Biogen’s high-dose SMA drug By Investing.com - Investing.com South Africa
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):